The FDA decision on Zuranolone, proposed for treating major depressive disorder and postpartum depression, is due on August 5, 2023.Zuranolone, a neuroactive steroid, is believed to work by targeting brain networks responsible for functions such as mood, arousal, behaviour, and cognition. Biogen Inc. (BIIB) and Sage Therapeutics Inc. (SAGE) are jointly developing Zuranolone in the U.S. The development of Zuranolone was intended to offer an improved alternative to Sage’s Zulresso, an approved drug for the treatment of postpartum depression.If all goes well as planned, Zuranolone could achieve blockbuster sales, according to analysts. SAGE closed Friday’s (Jul.28, 2023) trading at $34.96, down 2.35%.